Bionano Genomics Reports Second Quarter 2022 Financial Results and Highlights Recent Business Progress
- 73% year-over-year revenue growth in Q2 2022
- Achieved all 1H 2022 ELEVATE! milestones
- Strong balance sheet with
- Conference call today,
The Company executed its commercialization strategy, built scientific momentum by presenting data at key scientific meetings and drove utilization of the Saphyr system at leading institutions across the globe, with the following highlights:
Notable Highlights since the End of Q2 2022:
- A paper was published in Leukemia, from
MD Anderson Cancer Center, demonstrating the utility of OGM for myelodysplastic syndrome (MDS) prognostication. The authors reported that in up to 28% of MDS participants in the study, using OGM instead of traditional methods of analysis would have resulted in a different prognostic risk score or additional actionable variants. Prognostic risk scores are used to determine the therapeutic management that oncologists follow in MDS so different risk scores could mean different therapies and potentially better outcomes for patients.
Business Highlights in Q2 2022:
- Total revenue for Q2 2022 was
$6.7 million, a record quarter for the company.
- Grew the installed base of Saphyr systems from 176 at the end of Q1 2022 by 20 to 196 as of the end of Q2 2022. The installed base grew 62% compared to Q2 2021. The addition to the installed base of 20 systems in the second quarter of 2022 is 67% higher than the 12 systems that were added in the first quarter of 2022.
- Sold 3,394 nanochannel array flowcells during Q2 2022, a 24% growth over Q2 2021.
- Presented the latest research on OGM for use in a variety of applications at industry conferences including
American Association for Cancer Research(AACR) Annual Meeting, American Cytogenomics Conference(ACC), Advances in Genome Biology and Technology (AGBT) General Meeting, European Society of Human Genetics Conference ESHG), and European Association for Cancer Research (EACR) Congress.
- As mentioned as a highlight after the close of Q1, launched version 6.2 of NxClinical software with an integrated genomic scar analysis for homologous recombination deficiency (HRD). This feature provides a comprehensive, consistent, and automated analysis of biomarkers from next-generation sequencing (NGS) and microarray data that can help clinical researchers stratify therapeutic response across multiple tumor types.
- Announced, together with Hamilton, the collaborative development of the Long String VANTAGE for the isolation of Ultra High Molecular Weight (UHMW) DNA for use in OGM. The Long String VANTAGE is the first Assay Ready Workstation solution in Hamilton’s Long String Genomics product program and supports extraction of UHMW DNA at increased scale. We believe this workflow has the potential to double manual output, with increased confidence in sample yields and DNA quality.
- Q2 publications include:
- A study from the University Hospitals Leuven,
Belgiumusing OGM in combination with multiple other cytogenetic methods and a new single-cell analysis method as a comprehensive molecular strategy to characterize the genomic variation in B-cell acute lymphoblastic leukemia (B-ALL).
- An evaluation of OGM from
The First Affiliated Hospital of Zhengzhou, the largest hospital in Central China, highlighting the utility of OGM for structural variant analysis, including in a workflow for preimplantation genetic testing.
- The first peer-reviewed research study, from researchers at the University Hospital Essen, using OGM to analyze genetic aberrations found in pediatric patients with acute myeloid leukemia (AML).
- The publication of a multi-platform study from researchers in the
Human Genome Structural Variation Consortium(HGSVC) using OGM in combination with other cytogenetic technologies as a comprehensive strategy to investigate inversions that may lead to genetic disorders.
- A study from the University Hospitals Leuven,
- OGM using the Saphyr system continues to be adopted at cytogenetics laboratories and academic medical centers across the globe.
“We believe our Q2 2022 results, which include record quarterly revenues for Bionano, show that the foundation we laid in 2021 has carried us into 2022 and that the great progress demonstrated by this quarter’s growth in Saphyr system installed base reflects continued gains in market development and proof of concept. We were also pleased to see a number of presentations demonstrating OGM’s utility at cancer and cytogenomics conferences across
Q2 2022 Financial Highlights
- Total revenue for Q2 2022 was
$6.7 million, up 73% from Q2 2021, and a 17% increase from Q1 2022.
- Gross margin for Q2 2022 was 22%, compared to 37% from Q2 2021. The decrease was primarily due to low yields on our chip consumables produced at our contract manufacturer. Gross margin improved over the first quarter of 2022 of 15%, primarily due to improvements in chip yield.
- Q2 2022 GAAP operating expense was
$33.6 million, compared to $17.9 millionin Q2 2021. Q2 2022 non-GAAP1 operating expense was $26.4 million, compared to $16.1 millionin Q2 2021. Q2 2022 non-GAAP operating expense excludes $5.8 millionin stock-based compensation, and $1.4 millionin amortization of intangibles. The year-over-year increase was primarily due to increased headcount-related spending, increased research and development expenses, and increased marketing expenses.
June 30, 2022, the Company had cash, cash equivalents, and available-for-sale securities of $187.3 million.
|Conference Call & Webcast Details|
Participants may access a live webcast of the call on the Investors page of the Bionano website. To participate via telephone, please register here: https://register.vevent.com/register/BI1ae7bca48c2b4886928f5669d4b90c02. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on Bionano’s investor relations website at https://ir.bionanogenomics.com/ for at least 30 days.
Non-GAAP Financial Measures
To supplement Bionano’s financial results reported in accordance with
Bionano believes that non-GAAP operating expense is useful to investors and analysts as a supplement to its financial information prepared in accordance with GAAP for analyzing operating performance and identifying operating trends in its business. Bionano uses non-GAAP operating expense internally to facilitate period-to-period comparisons and analysis of its operating performance in order to understand, manage and evaluate its business and to make operating decisions. Accordingly, Bionano believes this measure allows for greater transparency with respect to key financial metrics it uses in assessing its own operating performance and making operating decisions.
This non-GAAP financial measure is not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP; has no standardized meaning prescribed by GAAP; and is not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; and the Company may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the Company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measure as used by Bionano in this press release and the accompanying reconciliation table has limits in its usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
For a reconciliation of non-GAAP operating expense to operating expense reported in accordance with GAAP, please refer to the financial tables accompanying this release.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “can,” “expect,” “may,” “plan,” “anticipate,” “should,” “believe,” “would,” “potential,” “outlook,” “guidance,” "goal", “will,” “estimate” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our expectations regarding product uptake, revenue growth and increased OGM adoption, including through publications highlighting the utility and applications of OGM; our growth prospects and future financial and operating results, including our 2022 revenue guidance and anticipated achievement of milestones, the growth of our installed Saphyr system base, the sales of our flowcell consumables and the other expectations related thereto; our ability to meet our goal to drive value and penetrate into our target markets; the anticipated benefits of the NxClinical software; our commercial expectations, including the potential market opportunity for structural variation analysis and OGM; the anticipated benefits and success of our collaboration efforts, including the opportunities offered by our anticipated collaboration with Hamilton; continued research, presentations and publications involving OGM, its utility compared to traditional cytogenetics and our technologies; our ability to drive adoption of OGM and our technology solutions; expected timing and results from our clinical studies; and the execution of our strategy, including the 2022 ELEVATE! strategy and our anticipated 2022 milestones. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic and geopolitical and macroeconomic events, such as the ongoing conflict between
|+1 (858) 888-7610|
|Investor Relations and|
|+1 (858) 366-3243|
|Condensed Consolidated Balance Sheet (Unaudited)|
|Cash and cash equivalents||$||27,159,000||$||24,571,000|
|Accounts receivable, net||4,851,000||4,934,000|
|Prepaid expenses and other current assets||3,509,000||4,481,000|
|Total current assets||216,288,000||272,414,000|
|Property and equipment, net||13,923,000||10,318,000|
|Operating lease right-of-use asset||6,431,000||6,691,000|
|Financing lease right-of-use asset||3,810,000||3,926,000|
|Intangible assets, net||24,005,000||26,842,000|
|Other long-term assets||841,000||749,000|
|Liabilities and stockholders’ equity|
|Operating lease liability||1,757,000||1,467,000|
|Finance lease liability, related party||292,000||299,000|
|Total current liabilities||27,908,000||21,840,000|
|Operating lease liability, net of current portion||5,075,000||5,288,000|
|Finance lease liability, net of current portion||3,632,000||3,642,000|
|Long-term contract liabilities||203,000||146,000|
|Additional paid-in capital||564,852,000||553,747,000|
|Accumulated other comprehensive loss||(1,918,000||)||(539,000||)|
|Total stockholders’ equity||284,734,000||337,118,000|
|Total liabilities and stockholders’ equity||$||321,552,000||$||377,100,000|
|Condensed Consolidated Statement of Operations (Unaudited)|
|Three Months Ended
||Six Months Ended
|Service and other revenue||2,757,000||1,360,000||5,337,000||2,479,000|
|Cost of revenue:|
|Cost of product revenue||3,973,000||1,869,000||7,549,000||3,383,000|
|Cost of service and other revenue||1,226,000||548,000||2,485,000||1,159,000|
|Total cost of revenue||5,199,000||2,417,000||10,034,000||4,542,000|
|Research and development||11,767,000||4,086,000||22,296,000||6,765,000|
|Selling, general and administrative||21,783,000||13,829,000||42,060,000||23,357,000|
|Total operating expenses||33,550,000||17,915,000||64,356,000||30,122,000|
|Loss from operations||(32,079,000||)||(16,476,000||)||(62,024,000||)||(27,640,000||)|
|Other income (expenses):|
|Gain on forgiveness of Paycheck Protection Program Loan||—||—||—||1,775,000|
|Loss on debt extinguishment||—||(2,076,000||)||—||(2,076,000||)|
|Other income (expense)||(156,000||)||(15,000||)||(188,000||)||(29,000||)|
|Total other income (expense)||(38,000||)||(2,301,000||)||(38,000||)||(1,078,000||)|
|Loss before income taxes||(32,117,000||)||(18,777,000||)||(62,062,000||)||(28,718,000||)|
|Provision for income taxes||(41,000||)||(9,000||)||(50,000||)||(15,000||)|
|Reconciliation of GAAP Operating Expense to Non-GAAP Operating Expense (Unaudited)|
|Three Months Ended
||Six Months Ended
|GAAP operating expense||$||33,550,000||$||17,915,000||$||64,356,000||$||30,122,000|
|Stock-based compensation expense||(5,777,000||)||(1,758,000||)||(10,879,000||)||(2,129,000||)|
|Intangible asset amortization||(1,419,000||)||(79,000||)||(2,838,000||)||(158,000||)|
|Adjusted non-GAAP operating expense||$||26,354,000||$||16,078,000||$||50,639,000||$||27,835,000|
1Non-GAAP operating expense is a non-GAAP financial measure. For a description of this non-GAAP financial measure, please refer to “Non-GAAP Financial Measures,” and for a reconciliation of non-GAAP operating expense to operating expense reporting in accordance with GAAP, please refer to the financial tables accompanying this release.
Source: Bionano Genomics